A 4-Week, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MK0686 in Patients With Osteoarthritis of the Knee or Hip

Merck Sharp & Dohme LLC0 sites150 target enrollmentSeptember 2005

ConditionsOsteoarthritis

DrugsMK0686

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Osteoarthritis
Sponsor: Merck Sharp & Dohme LLC
Enrollment: 150
Primary Endpoint: Pain relief at the knee and hip over 4 weeks of treatment as assessed by the WOMAC Pain Subscale.
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This study is being conducted to assess the safety and tolerability of MK-0686 and to evaluate its efficacy in the treatment of osteoarthritis of the hip or knee in men and women.

Registry

clinicaltrials.gov

Start Date

September 2005

End Date

May 2006

Last Updated

11 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Merck Sharp & Dohme LLC

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with a clinical and radiographic diagnosis of osteoarthritis of the hip or knee,either prior NSAID or Acetaminophen users within the ARA functional class I,II or III and with no clinically significant diseases
•Patients required to demonstrate a flare of the signs and symptoms of OA following withdrawal of NSAID treatment
•Prior acetaminophen users also required to demonstrate greater than a defined minimum level of signs and symptoms of OA
•females must be either post-menopausal or surgically sterilized